Treating Metastatic NSCLC: Choosing the Best Treatment for Optimal Outcomes
home / meeting-of-the-minds / treating-metastatic-nsclc-choosing-the-best-treatment-for-optimal-outcomes
A panel of oncology experts discusses treatment options, strategies, and patient care for metastatic NSCLC, with a focus on ALK and KRAS mutations.
EP. 1: Sarah’s Journey With ALK+ Metastatic NSCLC
Todd Bauer, MD;Sandip Patel, MD;Jonathan Riess, MD, MS ;Mary Grizzard, MSN, FNP ;Kasey Bamel, NP ;Cindy Ludovico, NP
December 23rd 2024A panel of experts review a case of a 55-year-old mom and high school teacher who received lorlatinib for ALK+ NSCLC with brain metastases.
EP. 2: The Role of Molecular Testing in Treatment Decisions for NSCLC
Todd Bauer, MD;Sandip Patel, MD;Jonathan Riess, MD, MS ;Mary Grizzard, MSN, FNP ;Kasey Bamel, NP ;Cindy Ludovico, NP
December 23rd 2024This video segment explores the critical role of biomarker testing in identifying patients with ALK-positive NSCLC, discussing the clinical characteristics that guide the use of ALK inhibitors and addressing challenges in implementing comprehensive molecular testing in community settings.
